Abstract
Background and Aims
Auto Mode use during the MiniMedTM 670G system clinical trials, in patients with type 1 diabetes (T1D) aged ≥7 years, demonstrated improved glycated hemoglobin levels and time spent in the target glucose range of 70-180 mg/dL (TIR), compared to Manual Mode (sensor-augmented pump therapy).1,2 Following the introduction of the system in Europe on October 2018, a performance assessment of real-life MiniMed™ 670G system use was conducted.
Methods
Data uploaded voluntarily to CareLinkTM Personal software from 01 October 2018 to 14 August 2019 by individuals living in Europe, who provided consent for their data to be aggregated, were analyzed. The percentage of time spent in the various glycemic ranges, mean sensor glucose (SG) levels, and the associated Glucose Management Indicator (GMI, the calculated estimate of HbA1c) were assessed when Auto Mode was turned OFF and when Auto Mode was turned ON.
Results
Data from 4’959 individuals living in 10 different countries were included in the analysis. When the Auto Mode feature was turned ON (4’369 individuals), mean SG was 151 mg/dL, corresponding to a GMI of 6.9%. The TIR was 73.1%, time spent <70 mg/dL was 2.3%, and time spent >180 mg/dL was 24.7%. Time spent at <54 mg/dL was 0.6%, representing less than10 minutes per day. These outcomes were similar for each of the countries.
Conclusions
European individuals using the MiniMed™ 670G system with the Auto Mode feature turned ON achieved internationally-recommended goals of glycemic control with TIR >70% and a GMI of <7%, while minimizing hypoglycemia.
